You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

83 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Sep 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
May 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Intent: Neoadjuvant
Updated
Oct 2025

Pages